Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting
Not Applicable
Completed
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Registration Number
- NCT01476280
- Lead Sponsor
- Incheon St.Mary's Hospital
- Brief Summary
Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting. Investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- ASA Physical Status 1 or 2
- Elective gynaecological laparoscopic surgery of ≥ 1h duration
Exclusion Criteria
- Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation
- Vomiting or retching in the 24 h preceding surgery
- Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry
- Ongoing vomiting from gastrointestinal disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Palonosetron palonosetron - Ramosetron Ramosetron -
- Primary Outcome Measures
Name Time Method Incidence of postoperative nausea and vomiting for 48 hours after surgery for 48 hours after surgery
- Secondary Outcome Measures
Name Time Method severity of nausea for 48 hours after surgery for 48 hours after surgery
Trial Locations
- Locations (1)
Incheon St. Mary's hospital
🇰🇷Incheon, Korea, Republic of